(Q44464289)

3 December 2017

Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance (English)

1 reference

3 December 2017

1 reference

Gianfranco Buccheri

1

1 reference

3 December 2017

Pierfederico Torchio

series ordinal

2

1 reference

3 December 2017

Domenico Ferrigno

series ordinal

3

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

97

1 reference

3 December 2017

12

1 reference

3 December 2017

3044-3052

1 reference

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

3 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

Abnormalities of blood coagulation tests in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Coagulation abnormalities in malignancy: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Coagulation disorders in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Fibrinolysis and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Laboratory diagnosis of the thrombophilic state in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Clotting factors in tumour tissue: implications for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Evaluating prethrombotic state in lung cancer using molecular markers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Prognostic significance of plasma D-dimer levels in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Haemostatic abnormalities in lung cancer: prognostic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Prognostic significance of blood coagulation tests in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Prognostic factors in stage I/II non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Prognostic value of stage grouping and TNM descriptors in lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Chemotherapy and survival in non-small cell lung cancer. The old vexata questio

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11432

7 January 2021

Identifiers

DOI

10.1002/CNCR.11432

1 reference

3 December 2017

1 reference